Aerami Therapeutics Announces Completion of Dosing in Phase 1 Trial of AER-901 (inhaled imatinib), a Critical Milestone Toward the Planned Initiation of a Phase 2 Trial in Pulmonary Arterial Hypertension (PAH) During the First Half of 2023 AER-901 (inhaled imatinib), a potential reverse-remodeling therapy, is being developed to address unmet need for PAH treatments that target pulmonary vascular remodeling while supporting ease-of-use...

Aerami Therapeutics Appoints Lisa Yañez as Chief Executive Officer Lisa Yañez Incoming Chief Executive OfficerAerami Therapeutics DURHAM, N.C., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Aerami Therapeutics Holdings, Inc (“Aerami”), a clinical-stage biopharmaceutical...

Aerami Therapeutics Appoints Lisa Yañez as Chief Operating Officer DURHAM, N.C., June 16, 2022 (GLOBE NEWSWIRE) -- Aerami Therapeutics, Inc. (the “Company”), a biopharmaceutical company focused on developing inhaled therapies to treat severe respiratory and other...

Aerami Therapeutics Announces Orphan Drug Designation for Imatinib for the Treatment of Pulmonary Arterial Hypertension Pulmonary arterial hypertension (PAH) affects almost 68,000 patients worldwide, with treatment limited to vasodilators, none of which are disease-modifyingDosing of patients in Phase 1 trial is...

Aerami Therapeutics Signs License Agreement with Hangzhou Chance Pharmaceuticals Co. Ltd. for Aerami’s PAH (pulmonary arterial hypertension) Drug Device Combination in China DURHAM, N.C., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Aerami Therapeutics, Inc. (“Aerami” or the “Company”) a clinical stage biopharmaceutical company developing inhaled therapies to treat severe...